-+ 0.00%
-+ 0.00%
-+ 0.00%

Scinai to Discuss Monoclonal Antibody PC111 for Rare Skin Diseases in Upcoming Webinar

Benzinga·05/01/2025 11:41:13
Listen to the news

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and which provides CDMO services through its Scinai Bioservices unit, today announced that it will be hosting a webinar on Wednesday May 7th at, at 11:30 AM EST / 18:30 Israel time. The webinar will address the unmet needs in treating Pemphigus Vulgaris and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and explore Pincell's PC111, a novel monoclonal antibody targeting soluble Fas ligand (sFasL) as a promising solution.